

REMARKS

With entry of this amendment, claims 1-22, 30, 38, and 40-44 are pending. The amendments are supported throughout the specification. For example, the amendment to claim 1 is supported, inter alia, by compound (f) at page 41. New claims 40-44 are supported, inter alia, at pages 125-126. Applicants await an Office Action on the merits.

Respectfully submitted,

January 10, 2002

Date



Matthew E. Mulkeen

Reg. No. 44,250

FOLEY & LARDNER

3000 K Street, N.W., Suite 500

Washington, D.C. 20007-5109

Telephone: (202) 672-5300


Facsimile: (202) 672-5399

Should additional fees be necessary in connection with the filing of this paper, or if a petition for extension of time is required for timely acceptance of same, the Commissioner is hereby authorized to charge Deposit Account No. 19-0741 for any such fees; and applicant(s) hereby petition for any needed extension of time.

20170106222400T

Marked-Up Version of the Amended Claims

1. (Once Amended) A compound of the formula (I)



wherein one of A and D represents a nitrogen atom and the other represents a carbon atom, or both represent a nitrogen atom;

B represents a nitrogen atom or a carbon atom;

m represents an integer from 0 to 3;

R¹, R² and R³ each represents (i) hydrogen or (ii) a group bound via a carbon atom, a nitrogen atom, an oxygen atom or a sulfur atom;

R⁴ represents a group bound via a carbon atom;

R⁵ represents (i) hydrogen, (ii) halogen or (iii) a group bound via a carbon atom or an oxygen atom;

R⁶ represents hydrogen or a group bound via a carbon atom;

R⁷ represents a homocyclic group which may be substituted or a heterocyclic group which may be substituted; and each dotted line represents a single bond or a double bond, **when each of A and D represents a nitrogen atom, then B represents a carbon atom;**

or a salt thereof.

30. (Once Amended) A pharmaceutical composition which comprises a compound of claim 1 or a salt thereof in a pharmaceutically acceptable carrier.

10042229.011102